News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RetroSense Therapeutics Completes pre-IND Meeting for RST-001


5/24/2012 10:15:50 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSense’s lead biologic, RST-001 for vision restoration in retinal degenerative conditions.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES